Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Colon Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR: PH2 Tuca+ Tras HER2+ CC View
Description: MOUNTAINEER: A Phase 2 Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617 SGNTUC-017)
Indication:
Rectal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR Ph2 Ak104 Cervical Cancer View
Description: A Phase 2 multicenter single-arm open-label study to evaluate the efficacy and safety of AK104 in subjects with recurrent or metastatic cervical cancer (AK104-201-AU)
Indication:
Cervical Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
PATHFINDER Early Detection Test Study View
Description: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice (GRAIL-007)
Indication:
Hematologic
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: IV
Title:
PATHFINDER Early Detection Test Study View
Description: The PATHFINDER Study: Assessment of the Implementation of an Investigational Multi-Cancer Early Detection Test into Clinical Practice (GRAIL-007)
Indication:
Solid Tumors
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: IV
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Anal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 Carbo/Pac NCMGA00012 MSCC View
Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)
Indication:
Carcinoid
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
PH3 Atez Tira Dura Sg 3 NSCLC View
Description: GO41854: A PHASE III OPEN-LABEL RANDOMIZED STUDY OF ATEZOLIZUMAB AND TIRAGOLUMAB COMPARED WITH DURVALUMAB IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER WHO HAVE NOT PROGRESSED AFTER CONCURRENT PLATINUM-BASED CHEMORADIATION (SKYSCRAPER-03)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 Sinti vs Placebo ESCC View
Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301
Indication:
Esophageal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
PH2 Brentux+CHP In Tx Naive PTCL View
Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)
Indication:
Lymphomas
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR KEAP1/NRF2 NSCLC View
Description: CX-839-014 "KEAPSAKE": A Phase 2 Randomized Multicenter Double-blind Study of the Glutaminase Inhibitor Telaglenastat with Pembrolizumab and Chemotherapy versus Placebo with Pembrolizumab and Chemotherapy in First-line Metastatic KEAP1/NRF2-mutated Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR-PH3 pral(Blu-667) RET-fusion mNSCLC View
Description: A Randomized Open-Label Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive Metastatic Non-Small Cell Lung Cancer (BLU-667-2303)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
Ph 3 Irino Oxa Flu Leu Pac + GEM mPan View
Description: An open-label randomised multicentre phase III study of irinotecan liposome injection oxaliplatin 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas (D-US-60010-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR PH 2 ASG-22CE Urothelial Cancer View
Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
Ph3 Fruq + Placebo CC (FRESCO-2) View
Description: A Global Multicenter Randomized Placebo-Controlled Phase 3 Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care to Placebo Plus Best Supportive Care in Patients with Refractory Metastatic Colorectal Cancer (FRESCO-2) (2019-013-GLOB1)
Indication:
Colon Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
Ph 3 BYL719 + nabpax TNBC PIK3CA View
Description: EPIK-B3: A phase III multicenter randomized double-blind placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with nab-paclitaxel in patients with advanced triple negative breast cancer with either phosphoinositide-3-kinase catalytic subunit alpha (PIK3CA) mutation or phosphatase and tensin homolog protein (PTEN) loss without PIK3CA mutation (CBYL719H12301)
Indication:
Breast Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Essential Thrombocythemia
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR PH3 Pacritinib vs MD choice in MF View
Description: A Randomized Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelets Counts <50000/µL) (PAC203)
Indication:
Myelofibrosis
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph2 Pemigatinib Solids FGFR View
Description: (INCB 54828-207) A Phase 2 Open-Label Single-Arm Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
Indication:
Solid Tumors
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR Ph 3 Tuca/Placbo + T-DM1 HER2+ View
Description: STAR: Randomized double-blind phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer (HER2CLIMB-02)(SGNTUC-016)
Indication:
Breast Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph2 Erdafitinib FGFR Solid Tumors View
Description: A Phase 2 Study of Erdafitinib in Subjects With Advanced Solid Tumors and FGFR Gene Alterations (42756493CAN2002)
Indication:
Solid Tumors
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View
Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)
Indication:
Lymphomas
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Anal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Biliary Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Bone Mets
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Brain Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Breast Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Uterine Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vaginal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Vulvar Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Rectal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Renal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Sarcoma
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Solid Tumors
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Testicular Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Thyroid Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Malignant Adenoma
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Ovarian Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Penile Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Peritoneal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gastric Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kaposi's Sarcoma
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Kidney Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Liver Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Cervical Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Colon Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Endometrial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Esophageal Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Fallopian Tube Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 MRTX849 Solids KRAS G12C View
Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)
Indication:
Gall Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
Ph3 GC4419 Oral Mucositis H&N View
Description: ROMAN: Reduction in Oral Mucositis with Avasopasem Manganese (GC4419)- Phase 3 Trial in Patients Receiving Chemoradiotherapy for Locally-Advanced Non-Metastatic Head and Neck Cancer (GTI-4419-301)
Indication:
Head and Neck Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Infigratinib vs Gem/Cis Cholangio View
Description: A Phase 3 Multicenter Open-Label Randomized Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)
Indication:
Biliary Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph3 ALK+ mNSCLC (Brigatinib-3001) View
Description: Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG®)Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Bladder Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR Sitra+Nivo/Pembro+Enfor Adv/Met Uro View
Description: A Phase 2 Study of Sitravatinib in Combination with PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma (516-003)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR Ph3 Nirap+Abirat+Pred mCRPC View
Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer(64091742PCR3001)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Lung Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Solid Tumors
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Ph1/2 BLU667 thy NSCLC Sol tum View
Description: A Phase 1/2 Study of the Highly-selective RET Inhibitor BLU-667 in Patients with Thyroid Cancer Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors
Indication:
Thyroid Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I/II
Title:
STAR Rucaparib v PhysC mCRPC (TRITON3) View
Description: TRITON3: A Multicenter Randomized Open-label Phase 3 Study of Rucaparib versus Physician's Choice of Therapy for Patients withMetastatic Castration-resistant Prostate Cancer Associated withHomologous Recombination Deficiency (CO-338-063)
Indication:
Prostate Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR BV in pts w/1L cHL or PTCL View
Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy
Indication:
Lymphomas
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: II
Title:
STAR Ph3 FGFR erdafitinib urothelial View
Description: (42756493BLC3001) A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations (THOR)
Indication:
Urothelial Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
PANOVA-3: 1L Gemcit + nab-pac pancreatic View
Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)
Indication:
Pancreatic Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: III
Title:
STAR Ph1 CX-4945 Basal Cell Carcinoma View
Description: A Phase I Multi-Center Open-Label Treatment Duration Increment Expansion Safety and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)
Indication:
Skin Cancer
Location:
Texas Oncology-El Paso Cancer Treatment Center Grandview
Phase: I